期刊文献+

基因芯片技术筛选前列腺癌雄激素去势抵抗相关基因 被引量:1

Microarray in screening of castration resistant prostate cancer associated genes
下载PDF
导出
摘要 目的利用基因芯片技术高通量筛选前列腺癌雄激素去势抵抗相关基因,为研究雄激素去势抵抗进展前列腺癌的分子机制奠定基础。方法提取并纯化LNCaP及C4~2细胞的总mRNA,反转录合成荧光分子标记的cDNA,与基因芯片杂交;采用Genepix Pr06.0图像分析软件分析,筛选表达差异的基因;KEGG富集分析每个pathway中差异基因富集的显著性。结果在表达谱芯片中筛选出417个差异表达基因,包括301个C4~2细胞中表达上调基因,116个表达下调基因;KEGG富集分析显示,与前列腺癌相关的表达差异的基因有GF、EGFR、HSP、BAD、P21、E2F、Raf、CyclinE、PSA和Pj3K等,其中EGFR、Raf表达差异最明显。结论EGFR、Raf基因表达异常可能在雄激素去势抵抗型前列腺癌的形成过程中发挥着重要作用,本研究为前列腺癌去势抵抗进展分子机制的探索提供了理论依据。 Objective To compare the gene expression profile associated with castration resistant prostate cancer (CRPC) of androgen sensitive LNCaP prostate cancer (PCa) cell line to the androgen resistant C4-2 PCa cell line and identify the possible mechanism of castration resistant prostate cancer. Methods LNCaP and C4-2 cell lines were cultured under standard conditions. Total RNA was extracted and purified, and then reverse transcript to cDNA, hybridized according to the Agilent chip instructions. The fluorescent signals were analyzed and displayed by using Genepix Pro6.0 to find differential expressed genes. KEGG transcriptional domain coverage analyzed the differential expressed genes involved in signaling pathway. Results Comparing C4-2 and LNCaP cell lines, there were 417 differential expressed genes, including 301 upregulated genes and 116 downregulated genes. KEGG transcriptional domain coverage revealed differentially expressed genes in PCa associated signaling pathway were GF, EGFR, HSP, BAD, P21, E2F, Raf, CyclinE, PSA and PI3K. EGFR and Raf were the most significantly differentially expressed genes in PCa associated signaling pathway. Conclusion 10 differential expressed genes in LNCaP and C4-2 cell lines are related to PCa associated signal pathway. EGFR and Raf may play an important function in the development of CRPC.
出处 《西部医学》 2014年第9期1113-1116,共4页 Medical Journal of West China
基金 国家自然科学基金(81272200) 陕西省国际合作项目(2011KW-45)
关键词 基因芯片 EGFR RAF LNCAP细胞 C4~2细胞 雄激素去势抵抗前列腺癌 microarray technology EGFR Raf LNCaP Cell C4-2 Cell Castration resistant prostate cancer
  • 相关文献

参考文献9

  • 1Gallotta A, Ziglioli F, Ferretti S, et al. A novel algorithm for the prediction of prostate cancer in clinically suspected patients [J]. Cancer Biomark, 2013, 13(4) :227 -34.
  • 2Abidi A. Cabazitaxel: A novel taxanefor metastatic castration- resistant prostate cancer-current implications and future pros pects [J]. J PharmacolPharmacother, 2013, 4(4):230-237.
  • 3殷杰,杨晓燕,虞佳,向琼,李倩,唐惠芳,雷小勇.基因芯片分析筛选BEL-7402与BEL-7402/FU细胞中的差异miRNA表达基因[J].国际病理科学与临床杂志,2012,32(5):374-378. 被引量:3
  • 4Shah RB, Ghosh D, Elder JT. Epidermal growth factor receptor (ErhB1) expression in prostate cancer progression., correlation with androgen independence [J]. Prostate,2006, 66: 1437.
  • 5Pignon JC, Koopmansch B, Nolens G, et al. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines [J]. Cancer Res,2009, 69 :2941-2949.
  • 6Caterina Peraldo Neia, Giorgia Migliardi, et al. Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene ex pression profiling and EGFR protein expression in primary pros rate cancer [J]. Bmc Cancer, 2011, 11:31. C.
  • 7ai CQ, Peng Y, Buckley MT, et al. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations [J]. Oncogene, 2008, 27(22):3201-3210.
  • 8McCubreyJA, Steelman LS, Chappell WH, etal. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transforma- tion and drug resistance [J]. Biochim Biophys Acta, 2007,1773 (8) : 1263-1284.
  • 9卢希,韩昱晨.Raf蛋白激酶与肿瘤治疗相关研究的现状[J].中华肿瘤防治杂志,2008,15(16):1270-1274. 被引量:2

二级参考文献21

  • 1张海波,吴万垠,柴小姝.艾迪注射液联合多西紫杉醇二线方案治疗32例ⅢB/Ⅳ期非小细胞肺癌的临床观察[J].中华肿瘤防治杂志,2006,13(18):1440-1440. 被引量:6
  • 2陆嘉德,郭晔.肿瘤靶向治疗新探:多靶点Raf激酶抑制剂[J].中国癌症杂志,2007,17(1):1-7. 被引量:12
  • 3Mclubrey J A, Steelman L S, Chappell W H, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance[J]. Biochim Biophys Acta, 2007, 1773 (8):1263-1284.
  • 4Sacks D B. The role of scaffold proteins in MEK/ERK signaling [J]. Biochem Soc Trans, 2006, 34(5):833-836.
  • 5Lee M. Clearing the trail for cancer therapy[J]. Cancer Cell, 2007,12(1):4-6.
  • 6Yuryev A, Ono M, Goff S A, et al. Isoform-specific localization of A RAF in mitochondria[J]. Mol Cell Biol, 2000,20 (3): 4870-4878.
  • 7Wan P T, Garnett M J, Roe S M, et al. Mechanism of activa tion ot the RAF ERK signaling pathway by oncogenic mutations of B RAF[J]. Cell, 2004, 116(6):855-867.
  • 8Klysik J, Theroux S J, Sedivy J M, et al. Singling crossroads: The function of Raf kinase inhibiting protein in cancer, the central nervous system and reproduction[J]. Cell signal, 2008,20 (1):1-9.
  • 9Schreck R, Rapp W R. Raf kinases: Oncogenesis and drug discovery[J]. Int J Cancer, 2006, 119(10) :2261-2271.
  • 10Ww S, Gco W, Fang B. Development of small-molecule inhibi tors of Raf[J]. Recent Patents Anti Infect Drug Disc, 2006,1 (2) :241-246.

共引文献2

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部